Please login to the form below
Histogenics
This page shows the latest Histogenics news and features for those working in and with pharma, biotech and healthcare.
Gyroscope advances gene therapy platform, merges with Orbit
News mirrors Ocugen and Histogenics merger. UK-based Gyroscope is to merge with Orbit Biomedical to further develop its gene therapy platform for eye diseases. ... The announcement comes hot on the heels of news of another two biotechs Histogenics and
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Histogenics names former MedImmune president as CEO
Peter Greenleaf to lead regenerative medicine company. Peter Greenleaf, the former president of AstraZeneca's (AZ) biologics arms MedImmune, has joined regenerative medicine company Histogenics as CEO. ... Peter's expertise in growing smaller biotech
Histogenics names former MedImmune president as CEO
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- bluebird bio provides update on 2seventy bio spin-off
- Award-winning health agency 90TEN launches in the US
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
